SMA is a hereditary disease with a well-characterised genetic cause.1-3 SMA is an autosomal recessive genetic disease in which two deleted or mutated SMN1 genes are inherited—1 from each parent.4
Share page
CARRIER SCREENING IS RECOMMENDED5
The American College of Medical Genetics and Genomics (ACMG) recommends that because SMA is found in all populations, carrier screening should be offered to couples of all races and ethnicities.
The ACMG suggests that the testing be performed either before conception or early in pregnancy to allow carriers to make informed reproductive choices.5
Molecular genetic testing is an important tool in the diagnosis of spinal muscular atrophy6,7
Adapted from D’Amico et al.6
WHICH GENES ARE RESPONSIBLE FOR THE SMA PHENOTYPE?
SMA in a disease of two genes: the determinant gene, SMN1, and the modifier gene, SMN2.
Watch video nowvideoWrapper1
The SMN gene deletion test is recommended as the first diagnostic step for a patient suspected to have SMA.
If a patient is found to have a single copy of the SMN1 gene and the clinical presentation is compatible with SMA, sequencing of the remaining SMN1 gene may identify subtle mutations and confirm the diagnosis.7
Share now
DIFFERENTIAL DIAGNOSES OF SMA
SMA results from homozygous deletions or mutations involving the SMN gene at locus 5q13 of chromosome 5. There are many rare neuromuscular disorders (e.g., Lambert-Eaton myasthenic syndrome, affecting 0.05-0.08/100,000 people a year).8 These disorders may involve mutations in a variety of different genes that are not associated with 5q13.
The differential diagnosis of 5q spinal muscular atrophy includes, but is not limited to:9
Spinal cord disorders
Neoplasms
Other myelopathies
Myopathies
Congenital myopathies:
Congenital myotonic dystrophy
Congenital muscular dystrophies
Muscular dystrophies
Mitochondrial myopathies
Acid maltase / Pompe disease
Other metabolic myopathies:
Inflammatory myopathies
Channelopathies
Neuropathies
Congenital hypomyelinating or axonal neuropathy
Hereditary motor and sensory neuropathies
Chronic inflammatory demyelinating polyneuropathy
Neuromuscular junction disorders
Botulism
Congenital myasthenic syndromes
Lambert-Eaton myasthenic syndrome
Autoimmune myasthenia gravis
Other motor neuron diseases
Spinal muscular atrophy with respiratory distress (SMARD)
Juvenile muscular atrophy of distal upper extremity (Hirayama disease)
Fazio-Londe disease
Brown-Vialetto-van Laere syndrome
Juvenile amyotrophic lateral sclerosis
Other non-5q SMAs
Other disorders
Chromosomal abnormalities
Prader-Willi syndrome
Central nervous system abnormalities
Share now
Genetic diseases are determined by the combination of genes for a particular trait that are on the chromosomes received from the father and the mother.4
The characters shown are real patients and the required consent to use their stories has been obtained from the patients and families. Photographs are for illustrative purposes only.
References
1. Lefebvre S, Bürglen L, Reboullet S, et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell 1995;80(1):155-165.
5. Prior TW; Professional Practice Guidelines Committee. Carrier screening for spinal muscular atrophy. Genet Med 2008;10(11):840-842.
6. D’Amico A, Mercuri E, Tiziano FD, Bertini E. Spinal muscular atrophy. Orphanet J Rare Dis 2011;6:71.
7. Mercuri E, et al. Diagnosis and management of spinal muscular atrophy: Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. Neuromuscl Disord 2018;28(2):103-115.
8. Wirtz PW, Nijnuis MG, Sotodeh M, et al. The epidemiology of myasthenia gravis, Lambert–Eaton myasthenic syndrome and their associated tumours in the northern part of the province of South Holland. J Neurol. 2003;250(6):698–701. doi: 10.1007/ s00415-003-1063-7
9. Darras BT, Royden Jones H Jr, Ryan MM, De Vivo DC, eds. Neuromuscular Disorders of Infancy, Childhood, and Adolescence: A Clinician’s Approach. 2nd Ed. London, UK: Elsevier; 2015.
